Premium
Melanoma: Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma (Adv. Therap. 8/2020)
Author(s) -
Pisarevsky Evgeni,
Blau Rachel,
Epshtein Yana,
BenShushan Dikla,
EldarBoock Anat,
Tiram Galia,
KoshrovskiMichael Shani,
Scomparin Anna,
Pozzi Sabina,
Krivitsky Adva,
ShenbachKoltin Gal,
Yeini Eilam,
Fridrich Lidar,
White Richard,
SatchiFainaro Ronit
Publication year - 2020
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.202070017
Subject(s) - polyglutamic acid , melanoma , conjugate , rational design , pharmacology , chemistry , cancer research , medicine , materials science , nanotechnology , biochemistry , mathematical analysis , mathematics
In article number 2000028 Ronit Satchi‐Fainaro and co‐workers present a novel polymeric system that simultaneously delivers a combination of drugs that target BRAF/ MEK mutations in melanoma. This system possesses an improved solubility, stability, and selective release by cathepsins in the tumor site. Hence, it exhibits synergistic activity, with superior efficacy and safety compared to each monodrug polymer conjugate and combinations of the free drugs.